Table 3 Heart failure therapy and response to heart failure treatment
|  | Overall (n = 92) | Early (n = 49) | Late (n = 43) | p-value |
|---|---|---|---|---|
Heart failure treatment initiation | 0.258 | |||
 Initiated | 63 (68) | 36 (73) | 27 (63) | |
 Adding to previous therapy | 5 (5) | 1 (2) | 4 (9) | |
 LVEF > 45% and no cardiac complaints | 24 (26) | 12 (24) | 12 (28) | |
Number of HF drugs | 0.162 | |||
 1 | 32 (47) | 20 (54) | 12 (39) | |
 2 | 28 (41) | 15 (41) | 13 (42) | |
 3 | 8 (12) | 2 (5) | 6 (19) | |
ACE inhibitors / ARB | 0.538 | |||
 n | 61 (90) | 34 (92) | 27 (87) | |
 % of target dose | 25 [16.7–50] | 25 [16.7–50] | 25 [25–41.5] | |
Beta-blockers | 0.183 | |||
 n | 39 (57) | 18 (49) | 21 (68) | |
 % of target dose | 25 [12.5–50] | 18.75 [12.5–25] | 25 [12.5–50] | |
MRA | Â | |||
 n | 6 (9) | 2 (5) | 4 (13) | |
 % of target dose | 37.5 [25–50] | 37.5 [25–50] | 37.5 [25–50] | |
Side effects | Â | |||
 Hypotension | 18 (26) | 10 (27) | 8 (26) | |
 Renal dysfunction | 3 (4) | 1 (3) | 2 (6) | |
 Other | 6 (9) | 3 (8) | 3 (10) | |
Duration of HF treatment (months) | 16.8 [4.8–29.8] | 14.6 [3.4–28.0] | 25.3 [10.1–35.2] | 0.038* |
Response to HF therapy | ||||
|  | Overall (n = 50) | (partial) recovery (n = 26) | No recovery (n = 24) | p-value |
Response to HF therapy | 0.011* | |||
 Early | 26 (51) | 18 (69) | 8 (33) | |
 Late | 24 (49) | 8 (31) | 16 (67) | |
Number of HF drugs | 0.669 | |||
 1 | 22 (44) | 12 (46) | 10 (42) | |
 2 | 20 (40) | 9 (35) | 11 (46) | |
 3 | 8 (16) | 5 (19) | 3 (12) | |
ACE inhibitors / ARB | 0.316 | |||
 n | 46 (92) | 23 (88) | 23 (96) | |
 % of target dose | 25 [16.7–50] | 25 [12.5–50] | 25 [25–50] | |
Beta-blockers | 0.713 | |||
 n | 29 (59) | 16 (62) | 14 (58) | |
 % of target dose | 25 [12.5–50] | 25 [12.5–50] | 37.5 [12.5–50] | |
Duration of HF treatment (months) | 21.9 [13.5–30.9] | 22.3 [13.5–30.9] | 25.9 [13.3–36.6] | 0.547 |